Ask AI
HER2+ EBC

CE / CME

Evolving Treatment Landscape for HER2-Positive Early Breast Cancer

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: April 29, 2026

Expiration: October 28, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How many people with breast cancer do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Based on data presented for the phase III DESTINY-Breast11 trial of neoadjuvant T-DXd with docetaxel/trastuzumab/pertuzumab (THP) vs dose-dense doxorubicin and cyclophosphamide (ddAC) with THP in patients with high-risk HER2-positive EBC, which of the following approximately describes the magnitude of improvement in pCR rates with T-DXd with THP?​

How confident are you in your answer?
4.

In your consultation with a patient who has HER2-positive EBC with residual node-positive disease following neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) therapy and surgery, which of the following guideline-recommended adjuvant therapy options would you recommend as most optimal based on the latest clinical data for iDFS?

How confident are you in your answer?
5.

Ms Roberts is a 49‑year‑old Black woman with stage IIIB, ER‑negative/HER2‑positive EBC​. She received neoadjuvant THP​ and preoperative therapy. Postsurgery pathology shows residual invasive disease in the breast and axillary nodes​. Your team recommends adjuvant HER2‑directed therapy​. Ms Roberts voices strong concerns regarding lung side effects she read about online and is concerned about missing work​ to receive infusion-based treatments. She is the primary caregiver for her mother with liver cirrhosis. She says to you, “I don’t want to stop early like my cousin did when the side effects got bad.”

 You are about to start adjuvant HER2 directed therapy for Ms Roberts. Which coordinated action now best operationalizes shared decision making and communication to improve her adherence and persistence to adjuvant care?

How confident are you in your answer?